We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+21.1%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
-$150M
(-5%)
Cap. Flow
-$428M
Cap. Flow
% of AUM
-14.96%
Top 10 Holdings %
Top 10 Hldgs %
28.09%
Holding
113
New
30
Increased
18
Reduced
43
Closed
20
Top Buys
| 1 |
GE HealthCare
GEHC
|
+$83.4M |
| 2 |
AbbVie
ABBV
|
+$76M |
| 3 |
Eli Lilly
LLY
|
+$55.8M |
| 4 |
Pfizer
PFE
|
+$43.5M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$40.4M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$72.7M |
| 2 |
Surgery Partners
SGRY
|
+$68.7M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$65.2M |
| 4 |
Merck
MRK
|
+$63.8M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$56.9M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Technology | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APLS
26
DELISTED
Apellis Pharmaceuticals
APLS
| $42.7M | 1.49% |
+468,700
| New | +$40.4M |
|
27
Boston Scientific
BSX
$65.4B
| $42.5M | 1.48% |
785,700
-64,300
| -8% | -$3.36M |
|
|
28
Ultragenyx Pharmaceutical
RARE
$2.88B
| $41.5M | 1.45% |
900,700
-1,226,200
| -58% | -$56.9M |
|
|
29
Pfizer
PFE
$143B
| $41M | 1.43% |
+1,117,467
| New | +$43.5M |
|
30
Immunovant
IMVT
$8.27B
| $39.6M | 1.38% |
2,085,000
+1,042,000
| +100% | +$19.4M |
|
31
Axsome Therapeutics
AXSM
$11.8B
| $39.2M | 1.37% |
545,000
-74,200
| -12% | -$5.47M |
|
|
IMGN
32
DELISTED
Immunogen Inc
IMGN
| $37.7M | 1.32% |
+1,997,800
| New | +$23.6M |
|
33
Zoetis
ZTS
$32.1B
| $37.4M | 1.31% |
217,000
-190,500
| -47% | -$32.9M |
|
34
Prothena Corp
PRTA
$453M
| $36.5M | 1.28% |
535,000
-533,200
| -50% | -$34.4M |
|
35
Vir Biotechnology
VIR
$1.59B
| $35M | 1.22% |
1,425,000
-215,200
| -13% | -$5.4M |
|
36
Immunocore
IMCR
$1.78B
| $34.5M | 1.2% |
575,000
-194,800
| -25% | -$11.1M |
|
37
Sarepta Therapeutics
SRPT
$1.82B
| $34.1M | 1.19% |
297,500
-118,500
| -28% | -$15.3M |
|
38
Arrowhead Research
ARWR
$10.5B
| $33M | 1.15% |
925,000
-816,300
| -47% | -$28.1M |
|
39
Biohaven
BHVN
$2.32B
| $31.7M | 1.11% |
1,325,000
-162,200
| -11% | -$2.79M |
|
40
Revolution Medicines
RVMD
$39.6B
| $28.8M | 1% |
1,075,000
-269,800
| -20% | -$6.62M |
|
41
Privia Health
PRVA
$3.39B
| $28.2M | 0.98% |
+1,079,806
| New | +$28.5M |
|
42
Phathom Pharmaceuticals
PHAT
$873M
| $27.9M | 0.98% |
1,949,700
-98,900
| -5% | -$1.14M |
|
43
Baxter International
BAX
$11.7B
| $27.6M | 0.96% |
+604,700
| New | +$26.3M |
|
|
FUSN
44
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $26.6M | 0.93% |
5,700,000
| – | – |
|
45
Rocket Pharmaceuticals
RCKT
$376M
| $26.3M | 0.92% |
1,326,000
+81,600
| +7% | +$1.65M |
|
|
BPMC
46
DELISTED
Blueprint Medicines
BPMC
| $26.2M | 0.92% |
+415,000
| New | +$22.6M |
|
47
Editas Medicine
EDIT
$457M
| $24.7M | 0.86% |
+3,000,000
| New | +$26.1M |
|
|
VTYX
48
DELISTED
Ventyx Biosciences
VTYX
| $22.7M | 0.79% |
692,500
-1,225,300
| -64% | -$42.2M |
|
49
Natera
NTRA
$38.9B
| $21.1M | 0.74% |
432,900
+183,000
| +73% | +$9.34M |
|
50
Lantheus
LNTH
$7B
| $20.6M | 0.72% |
+245,100
| New | +$22M |
|
Similar funds
NM
PWAM
CM
LJAC
NI
MCM
TS
TW
Avidity Partners Management's Q2 2023 Portfolio in Review
As of Q2 2023, Avidity Partners Management held 113 positions worth $2.86B, down 5% from $3.01B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Avidity Partners Management withdrew a net $428M in Q2 2023, closing 20 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $63.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology.
Against the trend, Avidity Partners Management opened a new position in GE HealthCare worth $84.9M.
- Avidity Partners Management's largest Q2 2023 buy was GE HealthCare: 1,045,400 shares worth $84.9M.
- Avidity Partners Management added most to Cencora in Q2 2023, an estimated $30M increase.
- Avidity Partners Management's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $72.7M.
- Avidity Partners Management fully exited Merck in Q2 2023, selling an estimated $63.8M.
- Avidity Partners Management's ten largest holdings make up 28% of its $2.86B portfolio in Q2 2023.
- Avidity Partners Management opened 30 new positions and closed 20 in Q2 2023.
- Avidity Partners Management's portfolio value fell 5% quarter-over-quarter to $2.86B.
Based on Avidity Partners Management's 13F filing for Q2 2023, filed 14 Aug 2023.